

[Click here to access the guidelines/NICE algorithm](#)

N&WICS - TA288 - Dapagliflozin in a dual therapy regimen in combination with metformin - Type 2 diabetes

Before providing patient identifiable data on this form, please confirm that the patient (or in the case of a minor or vulnerable adult with the parent/legal guardian/carer) has given appropriate explicit consent for sensitive personal information on this form to be passed to the CCG and/or CSU for processing this funding request and validating subsequent invoices. Consent given: ☐

If there is more than one NICE-approved treatment available, a discussion between the responsible clinician and the patient has taken place about the advantages and disadvantages of the treatments available. This has taken into consideration therapeutic need and whether or not the patient is likely to adhere to treatment. The most appropriate, least expensive, will be chosen (taking into account administration costs, dosage and price per dose) unless an order of preference is stated in the TAs. ☐

Patient NHS No:	Trust:	Practice Name:
Patient Hospital No: <input type="text"/>	Consultant Making Request: <input type="text"/>	Practice Postcode:
Patient's Initials and DoB:		Practice Code:
Notification Email Address: <input type="text"/> (@NHS.net account ONLY)		Contact name & number: <input type="text"/>
Start date of requested treatment: <input type="text"/>	Provider: <input type="checkbox"/> Private <input type="checkbox"/> NHS Supplier: <input type="checkbox"/> Homecare <input type="checkbox"/> Hospital	Sub-Type: <input type="text"/> N/A <input type="checkbox"/> (if applicable)

By completing this form, you confirm that you intend to use the requested medicinal product described below as agreed in the local commissioning statement. Any requests which fall outside of this use will require an individual funding request (IFR).

For support regarding IFRs, please contact: norfolkicd@nhs.net

For support regarding the criteria listed below, please contact: norfolknontariff@nhs.net

Please indicate whether patient meets the following NICE criteria:	Please tick
1. Dapagliflozin in a dual therapy regimen in combination with metformin is recommended as an option for treating type 2 diabetes, only if: <ul style="list-style-type: none">a sulfonylurea is contraindicated or not tolerated orthe person is at significant risk of hypoglycaemia or its consequences.	<input type="checkbox"/> Yes <input type="checkbox"/> No
2. Dapagliflozin in combination with insulin with or without other antidiabetic drugs is recommended as an option for treating type 2 diabetes.	<input type="checkbox"/> Yes <input type="checkbox"/> No
3. This recommendation has been updated and replaced by NICE's technology appraisal guidance on dapagliflozin in triple therapy for treating type 2 diabetes.	<input type="checkbox"/> Yes <input type="checkbox"/> No
4. People currently receiving dapagliflozin in a dual therapy regimen that is not recommended for them in 1.1 should be able to continue treatment until they and their clinician consider it appropriate to stop.	<input type="checkbox"/> Yes <input type="checkbox"/> No
I confirm that the patient meets the criteria for treatment	
Name of person completing: <input type="text"/>	Contact Details: <input type="text"/>
Designation of person completing: <input type="text"/>	Date: <input type="text"/>
Trust Authorising Pharmacist	
Name: <input type="text"/>	
Date: <input type="text"/>	